证券代码：600211 证券简称：西藏药业 公告编号：2025-039 西藏诺迪康药业股份有限公司 第八届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司第八届董事会第十一次会议通知于 2025 年 10 月 20 日以电邮和微信的方式发出， 会议于 2025 年 10 月 30 日以通讯方式召开。会议应出席董事 9 名，实际参加会议表决的董 事 9 名。会议由董事长陈达彬先生主持，公司高管列席了会议，会议的召开符合《公司法》 及《公司章程》的有关规定。 二、会议审议情况 1、公司 2025 年第三季度报告： 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过该议案。 公司 2025 年第三季度财务会计报告已经公司董事会审计委员会审议通过。 详见公司同日发布的《2025 年第三季度报告》。 一、会议召开情况 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过该议案。 该议案已经公司董事会审计委员会审议通过。 详见公司同日发布的《关于会计估计变更的公告》。 特此公告。 西藏诺迪康药业股 ...

Financial Performance - Q3 2025 revenue was CNY 438,565,754.61, a decrease of 21.79% year-over-year[3] - Total profit for Q3 2025 was CNY 173,133,451.88, down 7.39% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 154,454,092.55, reflecting an 8.46% decline year-over-year[3] - Basic earnings per share for Q3 2025 were CNY 0.48, a decrease of 9.56% year-over-year[3] - The weighted average return on net assets was 3.88%, a decrease of 0.81 percentage points compared to the previous year[3] - Total operating revenue for the first three quarters of 2025 was CNY 2,089,270,909.97, a decrease of 3.96% compared to CNY 2,175,443,351.59 in the same period of 2024[26] - Net profit for the first three quarters of 2025 was CNY 725,906,851.38, a decrease of 8.69% compared to CNY 795,146,775.01 in 2024[27] - The net profit attributable to the parent company's shareholders decreased to ¥721,777,210.07 from ¥791,866,935.56, representing a decline of approximately 8.8% year-over-year[29] - Basic and diluted earnings per share were both ¥2.24, compared to ¥2.46 in the previous year, reflecting a decline of approximately 8.9%[29] - The company reported cash inflows from investment activities of ¥3,330,412,806.08, down from ¥3,577,250,394.80, a decrease of approximately 6.9%[32] - The company received cash from sales of goods and services totaling ¥2,488,285,507.95, down from ¥2,638,932,481.82, a decrease of about 5.7%[31] Cash Flow and Management - Cash flow from operating activities for Q3 2025 was CNY 112,849,641.28, a decrease of 26.02% compared to the previous year[3] - Cash and cash equivalents increased to CNY 2,040,163,047.60 as of September 30, 2025, up 23.76% from CNY 1,648,214,061.09 at the end of 2024[22] - Cash flow from operating activities generated a net amount of ¥713,064,912.90, slightly down from ¥747,262,008.45, a decrease of about 4.6%[32] - Cash and cash equivalents at the end of the period increased to ¥1,455,350,854.94 from ¥977,320,175.24, marking an increase of approximately 48.8%[33] - The ending cash and cash equivalents balance decreased to $91.05 million from $218.23 million, a decline of 58.3%[43] - Total cash outflow from operating activities was $261.18 million, down from $396.01 million, a reduction of 34.1%[43] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,816,326,515.3, an increase of 22.52% from the end of the previous year[5] - Total assets reached CNY 5,816,326,515.37 as of September 30, 2025, an increase of 22.53% from CNY 4,747,338,341.13 at the end of 2024[23] - Total liabilities increased to CNY 1,875,568,911.39 as of September 30, 2025, compared to CNY 795,233,231.60 at the end of 2024[24] - The total liabilities decreased to CNY 273,353,388.05 from CNY 564,419,493.13, a reduction of 51.6%[36] - The company's total equity decreased to CNY 4,079,173,989.72 from CNY 4,130,836,383.18, a decline of 1.2%[36] Investments and Subsidiaries - The company invested $60 million in Accuredit Therapeutics Limited, acquiring a 40.82% stake, with the investment completed and included in the consolidated financial statements[12] - The company has established a new subsidiary, Accuredit Therapeutics Limited, which is now included in the consolidated financial statements[12] - The company’s long-term equity investments increased to CNY 379,978,194.91 as of September 30, 2025, compared to CNY 86,558,123.28 at the end of 2024[22] - The company's long-term equity investments increased to CNY 2,305,702,025.00 from CNY 2,014,799,653.37, an increase of 14.4%[35] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 28,119,542.03, an increase of 65.00% compared to CNY 17,025,333.28 in 2024[27] - Research and development expenses increased significantly to CNY 30,564,787.85, up from CNY 11,671,655.25, reflecting a growth of 161.5%[38] Financial Products and Cash Management - The company has a total cash management amount of 1,335 million CNY, with an unexpired balance of 655 million CNY[15] - The company has invested in various bank financial products, with amounts ranging from 1,000 to 10,000 CNY, and annualized returns between 1.00% and 2.30%[17] - The company’s cash management includes investments in fixed income and money market products[17] - The company reported a total of 6,500 million in fixed income products with an interest rate of 0.45%/1.79%/1 for the period ending December 12, 2025[21] - The company has issued 3,000 million in fixed income products with an interest rate range of 0.6%-2.0% for the period ending December 16, 2025[21] - The company has a total of 2,500 million in fixed income products with an interest rate of 0.5% to 1.9% for the period ending December 18, 2025[21] - The company has issued 1,800 million in fixed income products with an interest rate range of 1.0%-1.84% for the period ending December 31, 2025[21] - The company reported 4,000 million in fixed income products with an interest rate of 1.00%/1.83%/2 for the period ending November 28, 2025[21] - The company has a total of 2,500 million in fixed income products with an interest rate of 0.75%-1.90% for the period ending November 21, 2025[21] - The company issued 1,000 million in fixed income products with an interest rate of 1%/1.55%/1.65 for the period ending December 10, 2025[21] - The company has a total of 3,000 million in fixed income products with an interest rate of 0.5% to 1.9% for the period ending December 22, 2025[21] - The company reported 2,700 million in fixed income products with an interest rate of 1.0% or 1.73% for the period ending December 31, 2025[21] - The company has issued 1,000 million in fixed income products with an interest rate of 0.45%/1.83%/1 for the period ending December 25, 2025[21] Shareholder Information - Shareholders' equity attributable to the parent company was CNY 3,551,437,102.2, down 9.35% from the previous year-end[5] - The company has a total of 10,283,000 shares held by Beijing New Phoenix City Real Estate Development Co., Ltd. through margin financing[12] - The company has not reported any overdue amounts in its cash management activities[15] - The company has not experienced any changes in the lending/borrowing of shares among major shareholders during the reporting period[12]

Core Insights - The company reported a third-quarter revenue of 439 million, a year-on-year decrease of 21.79% [1] - The net profit for the third quarter was 154 million, reflecting a year-on-year decline of 8.46% [1] - For the first three quarters, the total revenue amounted to 2.089 billion, down 3.96% compared to the previous year [1] - The net profit for the first three quarters was 722 million, which is an 8.85% decrease year-on-year [1]

Group 1 - The core point of the news is that Tibet Pharmaceutical has experienced a significant decline in its stock price, dropping 5.05% on October 23, with a total market value of 14.366 billion yuan [1] - Tibet Pharmaceutical's stock has fallen for four consecutive days, with a cumulative decline of 4.63% during this period [1] - The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and only 0.20% from other sources [1] Group 2 - Among the top shareholders of Tibet Pharmaceutical, one fund from Huaxia Fund holds 1.9036 million shares, representing 0.59% of the circulating shares [2] - The Huaxia Industry Prosperity Mixed A fund has incurred a floating loss of approximately 4.5116 million yuan today, with a total floating loss of 4.3403 million yuan over the past four days [2] - The fund has achieved a return of 51.13% year-to-date and 55.43% over the past year, ranking 757 out of 8159 and 489 out of 8030 respectively [2]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Points - The announcement details the release of pledged shares by a major shareholder, Huaxi Pharmaceutical Group, which holds 56.15 million shares, accounting for 17.42% of the company's total shares [2] - After the release of the pledge, Huaxi Pharmaceutical has a total of 18.76 million shares pledged, representing 33.41% of its holdings and 5.82% of the company's total shares [2] - There are no plans for further pledging of the released shares [2] Summary by Sections - **Shareholder Information** - Huaxi Pharmaceutical Group is the second-largest shareholder of the company, holding 56.15 million shares [2] - **Pledge Details** - The release of the pledge has been completed, and the current pledged shares amount to 18.76 million [2] - **Future Plans** - There are no subsequent plans for pledging the released shares [2]

Group 1 - The core point of the article is that Tibet Pharmaceutical announced the release of share pledges by its second-largest shareholder, Huaxi Pharmaceutical Group, which holds 17.42% of the company's total shares [2] - Huaxi Pharmaceutical Group has released 1.34 million shares from pledge [2] - The total number of shares held by Huaxi Pharmaceutical Group amounts to 56.1483 million shares [2]

●西藏华西药业集团有限公司（以下简称"华西药业"）持有本公司 5,614.83 万股股份 （全部为无限售流通股），占本公司总股本的 17.42%，为本公司第二大股东；本次解除质押 后，华西药业持有本公司股份累计质押数量为 1,876 万股，占其持有本公司股份总数的 33.41%， 占本公司总股本的 5.82%。 本公司于近日收到华西药业通知，获悉其将所持有的本公司部分股份办理了解除质押业 务，相关手续已办理完毕，具体情况如下： 证券代码：600211 证券简称：西藏药业 公告编号：2025-038 西藏诺迪康药业股份有限公司 关于持股 5%以上的股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股东名称 | 西藏华西药业集团有限公司 | | --- | --- | | 本次解除质押股份 | 134 万股 | | 占其所持股份比例 | 2.39% | | 占公司总股本比例 | 0.42% | | 解除质押完成时间 | 2025 年 10 月 17 日 | | 持股数量 | 5,614 ...

Core Viewpoint - Tibet Pharmaceutical announced that Huaxi Pharmaceutical holds 56.1483 million shares, accounting for 17.42% of the total share capital, making it the second-largest shareholder of the company [1] Summary by Relevant Sections - Shareholding Details - Huaxi Pharmaceutical has released the pledge of 1.34 million shares, which represents 2.39% of its holdings and 0.42% of the total share capital [1] - After the release of the pledge, the remaining pledged shares amount to 18.76 million shares, accounting for 33.41% of its holdings and 5.82% of the total share capital [1] - Future Plans - There are no subsequent pledge plans for the released shares [1]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.13% on October 16, with Sanofi leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Biopharmaceutical Sector Performance - Sanofi (688336) saw a significant rise of 13.02%, closing at 59.90 with a trading volume of 177,400 shares and a transaction value of 1.063 billion [1] - Other notable gainers included: - Nossland (920047) up 4.09% to 25.46 with a transaction value of 125 million [1] - Rongchang Bio (688331) up 3.28% to 99.20 with a transaction value of 684 million [1] - Conversely, several companies experienced declines, including: - Anke Bio (300009) down 2.48% to 10.23 with a transaction value of 315 million [2] - Kain Technology (688687) down 1.92% to 28.62 with a transaction value of 169 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 2.7582 million from institutional investors, while retail investors experienced a net outflow of 140 million [2] - Notable capital inflows included: - Junshi Biosciences (688180) with a net inflow of 71.7936 million from institutional investors [3] - Sanofi (688336) with a net inflow of 67.508 million from institutional investors [3] - Conversely, significant outflows were observed in: - Sanofi (688336) with a retail net outflow of 540,300 [3] - Rongchang Bio (688331) with a retail net outflow of 4.41034 million [3]